Cambridge scientists report promising new findings on early use of targeted therapy in prostate cancer

A Cambridge-led clinical trial has revealed how a short course of targeted therapy prior to surgery can influence the biology of prostate cancer – even in men who do not carry known DNA repair gene mutations. CANCAP03, led by Dr Simon Pacey and Dr Harveer Dev published their findings in Clinical Cancer Research this month.

Read more on the CRUK Cambridge Centre blog.

Dev, H., et al., Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer, Clin Cancer Res June 2025 https://doi.org/10.1158/1078-0432.CCR-24-1304